Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.
暂无分享,去创建一个
Chia Huey Ooi | Sze Huey Tan | Jae Ho Cheong | Khay Guan Yeoh | Jimmy So | Alex Boussioutas | Chee Wee Ong | Jaffer A. Ajani | H. Grabsch | J. Ajani | Ju-Seog Lee | I. Tan | J. Cheong | S. Rozen | P. Tan | A. Boussioutas | N. Deng | J. So | W. Yong | K. Yeoh | S. Noh | W. Wong | S. Rha | M. Lee | S. Rha | T. Ivanova | Jeanie Wu | H. Toh | Ju-Seog Lee | Jeanie Wu | Ming Hui Lee | Patrick Tan | Tatiana Ivanova | Iain Beehuat Tan | Julian Lee | Wai Keong Wong | Heike Grabsch | Kiat Hon Lim | K. Lim | Han Chong Toh | Niantao Deng | Sung Hoon Noh | Sun Young Rha | C. Ong | Julian Lee | S. Tan | C. Ooi | A. Tsuburaya | W.K. Wan | M. Tellez | Wei Peng Yong | Akira Tsuburaya | Steven Rozen | Wei Kiat Wan | Manuel Salto Tellez | P. Tan | J. Wu
[1] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[2] Xiao-yan Chen,et al. Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of β-catenin , 2005, Clinical & Experimental Metastasis.
[3] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[4] T. Iwaya,et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. , 1998, Japanese journal of clinical oncology.
[5] Gordon K Smyth,et al. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.
[6] W. Dong,et al. Lentiviral‐mediated miRNA against liver‐intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer , 2010, Cancer science.
[7] M. Huflejt,et al. Galectin-4 in normal tissues and cancer , 2003, Glycoconjugate Journal.
[8] H. Yoo,et al. Expression profiling and subtype-specific expression of stomach cancer. , 2003, Cancer research.
[9] D. Park,et al. Protein Expression Profiling and Molecular Classification of Gastric Cancer by the Tissue Array Method , 2007, Clinical Cancer Research.
[10] Scott A. Hundahl,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.
[11] Yujin Hoshida,et al. Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.
[12] D. Cunningham,et al. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Histological classification of gastric adenocarcinoma for epidemiological research: concordance between pathologists. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[14] P. Rousseeuw. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis , 1987 .
[15] Yusuke Nakamura,et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray , 2004, Oncogene.
[16] K. Naka,et al. Expression of the E2F family in human gastrointestinal carcinomas , 1999, International journal of cancer.
[17] R. Simon,et al. Patient subsets and variation in therapeutic efficacy. , 1982, British journal of clinical pharmacology.
[18] Siew Hong Leong,et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. , 2003, Cancer research.
[19] Kenji Ikeda,et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.
[20] H. Sebastian Seung,et al. Learning the parts of objects by non-negative matrix factorization , 1999, Nature.
[21] L. Sobin,et al. The world health organization's histologic classification of gastrointestinal tumors: A commentary on the second edition , 1990, Cancer.
[22] D. Cox. Regression Models and Life-Tables , 1972 .
[23] E. Chu,et al. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. , 2009, Journal of the National Cancer Institute.
[24] M. Salto‐Tellez,et al. Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.
[25] J. Ajani,et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Izhak Haviv,et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. , 2003, Cancer research.
[27] P. Laurén,et al. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.
[28] Farin Kamangar,et al. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Haerting,et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W. Dong,et al. Altered Expression of a Li-Cadherin in Gastric Cancer and Intestinal Metaplasia , 2007, Digestive Diseases and Sciences.
[31] S. Ming. Gastric carcinoma: A pathobiological classification , 1977 .
[32] W J Macdonald,et al. GASTRIC CARCINOMA. , 1912, Canadian Medical Association journal.
[33] H. Aburatani,et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. , 2010, Gastroenterology.
[34] Y. Jeng,et al. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system , 2008, Modern Pathology.
[35] E. Gamelin,et al. Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[37] E. J. Neves,et al. Molecular Classifiers for Gastric Cancer and Nonmalignant Diseases of the Gastric Mucosa , 2004, Cancer Research.
[38] Y. Benjamini,et al. Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.
[39] D. Botstein,et al. Variation in gene expression patterns in human gastric cancers. , 2003, Molecular biology of the cell.
[40] Rui Li,et al. Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines , 2002, Oncogene.
[41] M. Koike,et al. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. , 1992, Gut.
[42] M. Salto‐Tellez,et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer , 2010, Modern Pathology.
[43] S. Bianchi,et al. Reproducibility of histologic classification of gastric cancer. , 1991, British Journal of Cancer.
[44] C. V. D. Velde,et al. Gastric cancer , 2009, The Lancet.
[45] J. Llovet,et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. , 2010, Seminars in liver disease.
[46] Kazuhiro Yoshida,et al. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer , 2005, Virchows Archiv.
[47] A. Ohtsu,et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.